Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

GLP-1 RA use increases risk for nonarteritic anterior ischemic optic neuropathy compared with other second-line antidiabetic medications.

New Delhi: Recommending to conduct post marketing surveillance (PMS) study in India, the Subject Expert Committee (SEC) ...

Weight-loss drugs spur debate and open new doors for CU Anschutz researcher studying food/brain relationshipOccasionally ...

Q2 2025 Earnings Call Transcript August 7, 2025 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.44. Operator: Good morning. My name is ...

Weight loss of at least 5% was associated with improvements in PROs among individuals with RMDs taking weight loss medications.

In Oklahoma, approximately 405,800 adults have diabetes, and every year, about 26,000 adults in the state are diagnosed with the disease, according to the American Diabetes Association. In America, ...

With salty snack dollars slumping, leveraging ‘sweet spots’ and navigating the ‘snackscape’ could help regain share ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...